<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575819</url>
  </required_header>
  <id_info>
    <org_study_id>FOR46-001</org_study_id>
    <nct_id>NCT03575819</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</brief_title>
  <official_title>A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fortis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fortis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and efficacy of FOR46 given every 21 days to patients with&#xD;
      metastatic castration-resistant prostate cancer.&#xD;
&#xD;
      The name of the study drug involved in this study is: FOR46 for Injection (FOR46)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46&#xD;
      in patients with metastatic castration-resistant prostate cancer. This study will be&#xD;
      conducted in two parts:&#xD;
&#xD;
      Dose escalation:&#xD;
&#xD;
      This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose&#xD;
      (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once&#xD;
      this dose is shown to be safe, a second patient will be enrolled at the next higher dose.&#xD;
      Patients will continue to be enrolled into either single or multiple patient groups receiving&#xD;
      increasing doses until the MTD is reached.&#xD;
&#xD;
      Dose expansion:&#xD;
&#xD;
      This part of the study will further evaluate the safety, tolerability and antitumor activity&#xD;
      of FOR46 at a dose shown to be safe in the dose escalation part of the study. Patients will&#xD;
      be enrolled into 1 of 2 groups, based on histology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Following completion of the dose escalation phase of the study and determination of a recommended phase 2 dose, patients will be enrolled into a dose expansion cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of toxicity</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Type, incidence, severity, seriousness, and relatedness of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>The severity and incidence of dose-limiting toxicities related to escalating dose levels of FOR46</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response/composite response</measure>
    <time_frame>12 months</time_frame>
    <description>Decline in serum prostate-specific antigen greater than 50% from baseline, confirmed by repeat measurement and objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize FOR46 plasma concentration</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the FOR46 area under the curve</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize FOR46 elimination</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>FOR46 elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug Antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Change from baseline in serum levels of antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median radiographic progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by Prostate Cancer Clinical Trials Working Group 3 criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Endpoint: Tumor expression of CD46</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <description>Association between level of tumor expression of CD46 by immunohistochemistry (IHC) analysis with clinical outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>FOR46 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOR46 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOR46</intervention_name>
    <description>FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46</description>
    <arm_group_label>FOR46 (Dose Escalation)</arm_group_label>
    <arm_group_label>FOR46 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male ≥ 18 years of age&#xD;
&#xD;
          -  Has histologically confirmed prostate cancer that is metastatic and has progressed as&#xD;
             defined by PCWG3 criteria during or after treatment with at least 1 ASI (eg,&#xD;
             abiraterone, enzalutamide, apalutamide), or another second-generation anti-androgen or&#xD;
             cytochrome P450 (CYP)17A1 inhibitor, with the most recent ASI administered in the&#xD;
             castration-resistant setting&#xD;
&#xD;
          -  Has serum testosterone levels &lt; 50 ng/dL during screening. Patients without a history&#xD;
             of bilateral orchiectomy are required to remain on luteinizing hormone-releasing&#xD;
             hormone (LHRH) analog during the course of protocol therapy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function&#xD;
&#xD;
          -  Males with female partners of childbearing potential must agree to use 2 effective&#xD;
             methods of contraception&#xD;
&#xD;
          -  Patients must provide signed informed consent&#xD;
&#xD;
          -  Patients enrolled into the dose expansion phase must have prostate carcinoma without&#xD;
             histologic evidence of small-cell/neuroendocrine carcinoma features on prior biopsy or&#xD;
             must have unequivocal histologic evidence of small-cell/neuroendocrine prostate&#xD;
             carcinoma (pure or mixed). Patients with treatment-emergent small-cell neuroendocrine&#xD;
             cancer (pure or mixed) may have received no more than on prior chemotherapy regimen&#xD;
             for mCRPC&#xD;
&#xD;
          -  Patients enrolled into the dose expansion phase must be willing to undergo a&#xD;
             metastatic tumor biopsy or has tissue available from a prior post-castration resistant&#xD;
             tumor biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistent clinically significant toxicities from previous anticancer therapy&#xD;
&#xD;
          -  Has NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic&#xD;
             disorder that is associated with peripheral neuropathy even without current&#xD;
             neuropathic manifestations&#xD;
&#xD;
          -  Prior treatment with cytotoxic chemotherapy for mCRPC (chemotherapy in the&#xD;
             hormone-sensitive setting is allowed if &gt; 6 months before study entry)&#xD;
&#xD;
          -  Has received external-beam radiation or systemic anticancer therapy within 14 days&#xD;
             before first dose of FOR46&#xD;
&#xD;
          -  Has received treatment with an investigational drug within 28 days before first dose&#xD;
             of FOR46&#xD;
&#xD;
          -  Has had a major surgical procedure within 28 days before administration of FOR46 dose&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled, clinically significant pulmonary disease&#xD;
&#xD;
          -  Has a history of brain or leptomeningeal metastases.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Has a known positive status for HIV or either active/chronic hepatitis B/C&#xD;
&#xD;
          -  Requires medications that are strong inhibitors or strong inducers of CYP3A4&#xD;
&#xD;
          -  [Dose escalation only] Has a history of episodic atrial fibrillation or flutter&#xD;
             (patients with chronic atrial fibrillation are not excluded)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Dorr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fortis Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Dorr, MD</last_name>
    <phone>858-504-1453</phone>
    <email>adorr414@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Abbey</last_name>
    <phone>925-286-0832</phone>
    <email>jill.abbey@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Institute of Urologic Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Bradley</last_name>
      <phone>310-794-3452</phone>
      <email>MABradley@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Rodriguez</last_name>
      <phone>310-794-2877</phone>
      <email>SaraRodriguez@mednet@ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Rettig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nela Pawlowska</last_name>
      <phone>415-353-7381</phone>
      <email>nela.pawlowska@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nana Owusu-Kwarteng</last_name>
      <phone>415-514-6363</phone>
      <email>Nana.Owusu-Kwarteng@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Carrera</last_name>
      <phone>312-695-8782</phone>
      <email>raquel.carrera@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Vanderweele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Entela Rama</last_name>
      <phone>313-576-9447</phone>
      <email>ramae@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Heath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>06903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naji Saker</last_name>
      <email>saker@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Vuky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>castration-resistant</keyword>
  <keyword>androgen-signaling blockade progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

